Key points are not available for this paper at this time.
The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.
Pautier et al. (Wed,) studied this question.